Quality of life among symptomatic compared to PSA-detected prostate cancer survivors: results from a UK wide patient-reported outcomes study

David W. Donnelly*, Linda C. Vis, Therese Kearney, L. Sharp, Damien Bennett, Sarah Wilding, Amy Downing, Penny Wright, Eila Watson, Richard Wagland, William R. Cross, Sabine Siesling, J.G. van Manen, Adam W. Glaser, Anna Gavin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Downloads (Pure)

Abstract

Background
Quality of life among prostate cancer survivors varies by socio-demographic factors and treatment type received; however, less in known about differences in functional outcomes by method of presentation. We investigate differences in reported urinary, bowel, sexual and hormone-related problems between symptomatic and PSA-detected prostate cancer survivors.

Methods
A UK wide cross-sectional postal survey of prostate cancer survivors conducted 18-42 months post-diagnosis. Questions were included on presentation method and treatment. Functional outcome was determined using the EPIC-26 questionnaire. Reported outcomes were compared for symptomatic and PSA-detected survivors using ANOVA and multivariable log-linear regression.

Results
Thirty-five thousand eight hundred twenty-three men responded (response rate: 60.8%). Of these, 31.3% reported presenting via PSA test and 59.7% symptomatically. In multivariable analysis, symptomatic men reported more difficulty with urinary incontinence (Adjusted mean ratio (AMR): 0.96, 95% CI: 0.96-0.97), urinary irritation (AMR: 0.95, 95% CI: 0.95-0.96), bowel function (AMR: 0.97, 95% CI: 0.97-0.98), sexual function (AMR: 0.90, 95% CI: 0.88-0.92), and vitality/hormonal function (AMR: 0.96, 95% CI: 0.96-0.96) than PSA-detected men. Differences were consistent across respondents of differing age, stage, Gleason score and treatment type.
Conclusion
Prostate cancer survivors presenting symptomatically report poorer functional outcomes than PSA-detected survivors. Differences were not explained by socio-demographic or clinical factors. Clinicians should be aware that men presenting with symptoms are more likely to report functional difficulties after prostate cancer treatment and may need additional aftercare if these difficulties persist. Method of presentation should be considered as a covariate in patient-reported outcome studies of prostate cancer.

Original languageEnglish
Article number947
JournalBMC cancer
Volume19
DOIs
Publication statusPublished - 15 Oct 2019

Fingerprint

Survivors
Prostatic Neoplasms
Quality of Life
Outcome Assessment (Health Care)
Demography
Aftercare
Neoplasm Grading
Urinary Incontinence
Therapeutics
Patient Reported Outcome Measures
Linear Models
Analysis of Variance
Cross-Sectional Studies
Hormones
Neoplasms
Surveys and Questionnaires

Cite this

Donnelly, David W. ; Vis, Linda C. ; Kearney, Therese ; Sharp, L. ; Bennett, Damien ; Wilding, Sarah ; Downing, Amy ; Wright, Penny ; Watson, Eila ; Wagland, Richard ; Cross, William R. ; Siesling, Sabine ; van Manen, J.G. ; Glaser, Adam W. ; Gavin, Anna. / Quality of life among symptomatic compared to PSA-detected prostate cancer survivors : results from a UK wide patient-reported outcomes study. In: BMC cancer. 2019 ; Vol. 19.
@article{f45de0eb3f904bec878cb472fc8b483f,
title = "Quality of life among symptomatic compared to PSA-detected prostate cancer survivors: results from a UK wide patient-reported outcomes study",
abstract = "BackgroundQuality of life among prostate cancer survivors varies by socio-demographic factors and treatment type received; however, less in known about differences in functional outcomes by method of presentation. We investigate differences in reported urinary, bowel, sexual and hormone-related problems between symptomatic and PSA-detected prostate cancer survivors.MethodsA UK wide cross-sectional postal survey of prostate cancer survivors conducted 18-42 months post-diagnosis. Questions were included on presentation method and treatment. Functional outcome was determined using the EPIC-26 questionnaire. Reported outcomes were compared for symptomatic and PSA-detected survivors using ANOVA and multivariable log-linear regression.ResultsThirty-five thousand eight hundred twenty-three men responded (response rate: 60.8{\%}). Of these, 31.3{\%} reported presenting via PSA test and 59.7{\%} symptomatically. In multivariable analysis, symptomatic men reported more difficulty with urinary incontinence (Adjusted mean ratio (AMR): 0.96, 95{\%} CI: 0.96-0.97), urinary irritation (AMR: 0.95, 95{\%} CI: 0.95-0.96), bowel function (AMR: 0.97, 95{\%} CI: 0.97-0.98), sexual function (AMR: 0.90, 95{\%} CI: 0.88-0.92), and vitality/hormonal function (AMR: 0.96, 95{\%} CI: 0.96-0.96) than PSA-detected men. Differences were consistent across respondents of differing age, stage, Gleason score and treatment type.ConclusionProstate cancer survivors presenting symptomatically report poorer functional outcomes than PSA-detected survivors. Differences were not explained by socio-demographic or clinical factors. Clinicians should be aware that men presenting with symptoms are more likely to report functional difficulties after prostate cancer treatment and may need additional aftercare if these difficulties persist. Method of presentation should be considered as a covariate in patient-reported outcome studies of prostate cancer.",
author = "Donnelly, {David W.} and Vis, {Linda C.} and Therese Kearney and L. Sharp and Damien Bennett and Sarah Wilding and Amy Downing and Penny Wright and Eila Watson and Richard Wagland and Cross, {William R.} and Sabine Siesling and {van Manen}, J.G. and Glaser, {Adam W.} and Anna Gavin",
year = "2019",
month = "10",
day = "15",
doi = "10.1186/s12885-019-6164-5",
language = "English",
volume = "19",
journal = "BMC cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

Donnelly, DW, Vis, LC, Kearney, T, Sharp, L, Bennett, D, Wilding, S, Downing, A, Wright, P, Watson, E, Wagland, R, Cross, WR, Siesling, S, van Manen, JG, Glaser, AW & Gavin, A 2019, 'Quality of life among symptomatic compared to PSA-detected prostate cancer survivors: results from a UK wide patient-reported outcomes study', BMC cancer, vol. 19, 947. https://doi.org/10.1186/s12885-019-6164-5

Quality of life among symptomatic compared to PSA-detected prostate cancer survivors : results from a UK wide patient-reported outcomes study. / Donnelly, David W.; Vis, Linda C.; Kearney, Therese; Sharp, L.; Bennett, Damien; Wilding, Sarah; Downing, Amy; Wright, Penny ; Watson, Eila; Wagland, Richard; Cross, William R.; Siesling, Sabine ; van Manen, J.G.; Glaser, Adam W.; Gavin, Anna.

In: BMC cancer, Vol. 19, 947, 15.10.2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Quality of life among symptomatic compared to PSA-detected prostate cancer survivors

T2 - results from a UK wide patient-reported outcomes study

AU - Donnelly, David W.

AU - Vis, Linda C.

AU - Kearney, Therese

AU - Sharp, L.

AU - Bennett, Damien

AU - Wilding, Sarah

AU - Downing, Amy

AU - Wright, Penny

AU - Watson, Eila

AU - Wagland, Richard

AU - Cross, William R.

AU - Siesling, Sabine

AU - van Manen, J.G.

AU - Glaser, Adam W.

AU - Gavin, Anna

PY - 2019/10/15

Y1 - 2019/10/15

N2 - BackgroundQuality of life among prostate cancer survivors varies by socio-demographic factors and treatment type received; however, less in known about differences in functional outcomes by method of presentation. We investigate differences in reported urinary, bowel, sexual and hormone-related problems between symptomatic and PSA-detected prostate cancer survivors.MethodsA UK wide cross-sectional postal survey of prostate cancer survivors conducted 18-42 months post-diagnosis. Questions were included on presentation method and treatment. Functional outcome was determined using the EPIC-26 questionnaire. Reported outcomes were compared for symptomatic and PSA-detected survivors using ANOVA and multivariable log-linear regression.ResultsThirty-five thousand eight hundred twenty-three men responded (response rate: 60.8%). Of these, 31.3% reported presenting via PSA test and 59.7% symptomatically. In multivariable analysis, symptomatic men reported more difficulty with urinary incontinence (Adjusted mean ratio (AMR): 0.96, 95% CI: 0.96-0.97), urinary irritation (AMR: 0.95, 95% CI: 0.95-0.96), bowel function (AMR: 0.97, 95% CI: 0.97-0.98), sexual function (AMR: 0.90, 95% CI: 0.88-0.92), and vitality/hormonal function (AMR: 0.96, 95% CI: 0.96-0.96) than PSA-detected men. Differences were consistent across respondents of differing age, stage, Gleason score and treatment type.ConclusionProstate cancer survivors presenting symptomatically report poorer functional outcomes than PSA-detected survivors. Differences were not explained by socio-demographic or clinical factors. Clinicians should be aware that men presenting with symptoms are more likely to report functional difficulties after prostate cancer treatment and may need additional aftercare if these difficulties persist. Method of presentation should be considered as a covariate in patient-reported outcome studies of prostate cancer.

AB - BackgroundQuality of life among prostate cancer survivors varies by socio-demographic factors and treatment type received; however, less in known about differences in functional outcomes by method of presentation. We investigate differences in reported urinary, bowel, sexual and hormone-related problems between symptomatic and PSA-detected prostate cancer survivors.MethodsA UK wide cross-sectional postal survey of prostate cancer survivors conducted 18-42 months post-diagnosis. Questions were included on presentation method and treatment. Functional outcome was determined using the EPIC-26 questionnaire. Reported outcomes were compared for symptomatic and PSA-detected survivors using ANOVA and multivariable log-linear regression.ResultsThirty-five thousand eight hundred twenty-three men responded (response rate: 60.8%). Of these, 31.3% reported presenting via PSA test and 59.7% symptomatically. In multivariable analysis, symptomatic men reported more difficulty with urinary incontinence (Adjusted mean ratio (AMR): 0.96, 95% CI: 0.96-0.97), urinary irritation (AMR: 0.95, 95% CI: 0.95-0.96), bowel function (AMR: 0.97, 95% CI: 0.97-0.98), sexual function (AMR: 0.90, 95% CI: 0.88-0.92), and vitality/hormonal function (AMR: 0.96, 95% CI: 0.96-0.96) than PSA-detected men. Differences were consistent across respondents of differing age, stage, Gleason score and treatment type.ConclusionProstate cancer survivors presenting symptomatically report poorer functional outcomes than PSA-detected survivors. Differences were not explained by socio-demographic or clinical factors. Clinicians should be aware that men presenting with symptoms are more likely to report functional difficulties after prostate cancer treatment and may need additional aftercare if these difficulties persist. Method of presentation should be considered as a covariate in patient-reported outcome studies of prostate cancer.

U2 - 10.1186/s12885-019-6164-5

DO - 10.1186/s12885-019-6164-5

M3 - Article

VL - 19

JO - BMC cancer

JF - BMC cancer

SN - 1471-2407

M1 - 947

ER -